ArticleBone marrow transplantation2026
An extraction pipeline for analysis of hematopoietic stem cell transplantation data.
Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many clinical studies are based on registry analyses, but exact approaches of data extraction and pre-processing are rarely included, while this is critical for reliability and reproducibility of results. We aimed to develop an open-source data extraction pipeline which generates a ready-to-analyze dataset focused on relevant determinants of outcomes after hematopoietic stem cell transplantation (HSCT). This pipeline was developed using EBMT registry data, including 54,457 allogeneic and 63,651 autologous HSCT procedures. The pipeline determines HLA matching from molecular data, assesses cytogenetic risk for acute myeloid leukemia and myelodysplastic syndrome, processes molecular markers, assigns the hematopoietic cell transplantation comorbidity index (HCT-CI) based on comorbidities, and maps disease states to simplified categories. We prospectively assessed the recently developed disease risk stratification system (DRSS), showing that the pipeline produces consistent results with previous studies. The hazard ratio correlation between our cohort and the original DRSS derivation cohort was 0.92 with a 2-year AUC of 0.616, indicating similar effects and predictive performance. We aim to establish a new standard by promoting transparent, standardized and uniform extraction of registry data, enhancing reproducibility in registry studies.
Indexed as
Identifiers
41807606What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.